Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the…
Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the…
The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.
Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…
The use of pharmacotherapies for the treatment of generalized anxiety disorder (GAD) has grown sharply, fueled by an increasing prevalence of the disorder and constrained access to nonpharmacologic…
The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…
The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already…
The unipolar depression market is crowded and highly genericized. The prominent use of SSRIs and, to a lesser extent, SNRIs as early-line treatments contributes to the challenges branded therapies…
Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon,…